Key Highlights

  • Kiniksa Pharmaceuticals (NASDAQ:KNSA) reports third-quarter results before the open on Tuesday, October 27, 2026, with consensus earnings of USD 0.31 per share against USD 0.30 diluted in the second quarter.
  • Second-quarter revenue, all from Arcalyst, rose about 55% to USD 243.6 million, and net income increased to USD 25.4 million from USD 17.8 million a year earlier.
  • Management raised 2026 Arcalyst net revenue guidance to USD 980 million to USD 995 million from USD 930 million to USD 945 million in its release of Tuesday, July 28, 2026.
  • Cash and short-term investments were USD 525.9 million with no debt, and the pipeline asset KPL-387 is in a pivotal Phase 3 study for recurrent pericarditis.

The Setup and the Raised Guide

Kiniksa Pharmaceuticals (NASDAQ:KNSA) sells Arcalyst, a treatment for recurrent pericarditis, which is repeated inflammation of the sac around the heart, and it reports before the open on Tuesday, October 27, 2026. Consensus earnings are USD 0.31 per share, and the company has a market value near USD 5.71 billion. In the second quarter, total revenue of USD 243.6 million compared with USD 156.8 million a year earlier, and diluted earnings were USD 0.30 against USD 0.23. The guidance raise of USD 50 million at both ends of the range left a new full-year Arcalyst range of USD 980 million to USD 995 million. Results cannot be known in advance.

Why Arcalyst Demand and KPL-387 Matter

Kiniksa Pharmaceuticals (NASDAQ:KNSA) depends on a single marketed product, so growth in the number of patients treated, the length of therapy and the net price after rebates drive nearly all results. A rise of about 55% in the second quarter shows strong uptake, and the question is how long the pace can continue as the treated population matures. The pipeline gives a second leg. KPL-387, an antibody aimed at the same inflammatory pathway, selected a 300 mg monthly subcutaneous dose for Phase 3, with a median time to treatment response of 4.0 days in Phase 2. The pivotal study, called PASTORALE, is enrolling up to about 85 participants, and commercial launch is targeted for 2028 or 2029.

Risks and What to Watch

The bull case for Kiniksa Pharmaceuticals (NASDAQ:KNSA) is Arcalyst sales that track toward or above the top of the USD 980 million to USD 995 million range, earnings above USD 0.31 and a further guidance lift, which would extend a strong post-July rerating, as shares rose about 21% after the second-quarter report. The bear case is a sequential slowdown in prescriptions, higher spending on research and selling costs, or a guidance range left unchanged, since a single-product company is judged on its growth rate. Competitive therapies and payer pressure on pricing are further risks. Investors should watch Arcalyst revenue against the implied fourth-quarter run rate, gross to net adjustments, operating expenses and enrolment news for KPL-387.

Where Things Stand

The answer is that Kiniksa Pharmaceuticals (NASDAQ:KNSA) can beat a USD 0.31 consensus if Arcalyst keeps its second-quarter momentum, but the reaction will likely rest on whether the USD 980 million to USD 995 million range is lifted again. With no debt and USD 525.9 million of cash, financial risk is low. The next catalysts are the release before the open on Tuesday, October 27, 2026, the Federal Reserve decision on Wednesday, October 28, 2026 and the planned start of a Phase 1 study of KPL-1161 by the end of 2026. Consensus figures are estimates, not guarantees, and this is not investment advice.